New York Times Front Page Story Features HIFU Prostate Cancer Treatment with Sonablate 500 from Misonix Incorporated

FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, today reported that the January 18, 2008 issue of The New York Times contained a cover story featuring the use of high intensity focused ultrasound (“HIFU”) for prostate cancer treatment performed with the Sonablate®500 (“SB500”) manufactured by Misonix.
MORE ON THIS TOPIC